Chondrosarcoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera

Chondrosarcoma emerging therapies such as INBRX-109, TIBSOVO (ivosidenib), and others are expected to boost the Chondrosarcoma Market in the upcoming years.

DelveInsight has launched a new report on "Chondrosarcoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample report @ https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Chondrosarcoma Market Report:

In 2023, the total number of new cases of chondrosarcoma in the 7MM was approximately 2,300. Chondrosarcoma, a type of bone cancer, is classified into four grades: I, II, III, and IV, with the majority of cases being Grade II. This cancer predominantly affects adults and is the second most common primary bone tumor after osteogenic sarcoma.
Currently, there are no approved therapies for chondrosarcoma, making the development of targeted molecular drugs and immunotherapies that improve clinical outcomes and reduce recurrence in patients with advanced chondrosarcoma a promising opportunity in the market.
Surgery is the primary treatment, although radiotherapy and chemotherapy are also commonly used. However, resistance to these conventional methods often leaves surgical resection as the only viable option for both primary and secondary chondrosarcoma, presenting a significant treatment challenge.
Chemotherapy and radiotherapy offer limited benefits for conventional chondrosarcoma, the most common form of primary chondrosarcoma. Innovative treatments targeting IDH mutations may provide hope in the chondrosarcoma treatment space, as approximately 65% of cases are linked to IDH mutations, opening up a substantial untapped market.
According to the updated NCCN guidelines, ivosidenib has been approved as a treatment option for patients with IDH1-mutant conventional or dedifferentiated chondrosarcoma. Additionally, the ESMO's 2021 clinical practice guidelines suggest trabectedin as a potential treatment for mesenchymal chondrosarcoma.
INBRX-109 is one of the leading emerging therapies, offering a novel treatment for patients with unresectable conventional chondrosarcoma, potentially extending progression-free survival (PFS) with an improved safety profile.
According to the analysis, conventional chondrosarcomas account for approximately 80% of all chondrosarcoma cases.
The total Chondrosarcoma Market size in the United States was around USD 8.5 million in 2023 and is expected to grow over the forecast period from 2024 to 2034.
Key Chondrosarcoma companies such as Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others are evaluating new drugs for Chondrosarcoma to improve the treatment landscape.
Promising Chondrosarcoma pipeline therapies in various stages of development include INBRX-109, TIBSOVO (ivosidenib), and others.
Key benefits of the Chondrosarcoma market report:
Chondrosarcoma market report covers a descriptive overview and comprehensive insight of the Chondrosarcoma Epidemiology and Chondrosarcoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Chondrosarcoma market report provides insights on the current and emerging therapies.
Chondrosarcoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Chondrosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market.

Got queries? Click here to know more about the Chondrosarcoma Market Landscape https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chondrosarcoma Overview

Chondrosarcoma is a group of locally aggressive or malignant tumors that produce a cartilaginous matrix, exhibiting a range of morphological characteristics and clinical behaviors. These tumors primarily develop in bones formed through endochondral ossification, making it the most common bone sarcoma in individuals over the age of 20. It mostly affects people in their fourth to sixth decades of life, with the pelvis being the most commonly affected site, followed by the femur, humerus, and ribs. The histologic grade of chondrosarcoma lesions is the most significant factor for prognosis.

The diagnosis of chondrosarcoma involves a detailed process, starting with a review of the patient's medical history and a physical examination to identify any potential signs and symptoms. Imaging tests, including X-rays, CT scans, and MRI scans, are used to visualize the tumor, determine its size, location, and extent. If a tumor suspected of being chondrosarcoma is found, a biopsy is conducted to collect a tissue sample for microscopic analysis by a pathologist, confirming the diagnosis. The tumor tissue is then graded on a scale from I to IV, based on its appearance under the microscope, which helps assess its aggressiveness and prognosis. Staging tests may also be performed to determine the extent of cancer spread.

Chondrosarcoma Treatment Market

The malignancy grade and the specific subtype of chondrosarcoma play a significant role in determining both the treatment approach and prognosis. Regardless of the subtype, the cornerstone of curative treatment for chondrosarcoma is adequate surgery. For high and intermediate-grade tumors, Enneking's approach recommends wide compartmental tumor resection, which can effectively control the tumor both locally and systemically in a curative context. In the case of low-grade chondrosarcoma, intralesional or marginal resection may be sufficient. Conventional chondrosarcomas are generally resistant to standard chemotherapy and radiotherapy. However, neoadjuvant or adjuvant chemotherapy may offer a survival benefit for patients with dedifferentiated chondrosarcoma. The chemotherapy regimen typically involves a combination of doxorubicin and cisplatin or ifosfamide.

To know more about the chondrosarcoma treatment algorithms, visit: https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chondrosarcoma Market Outlook

The current management of chondrosarcoma depends on factors such as the tumor type, grade, and location, with the grading system from I to III serving as the best predictor of clinical behavior. Surgical treatment is well-established as the most effective and primary approach, as other treatments like radiotherapy and chemotherapy are generally ineffective. Curettage, radical resection, and amputation are the main surgical options, with the choice of procedure depending on factors such as tumor size, location, and malignancy degree.

A significant challenge in estimating the revenue generated by systemic agents for chondrosarcoma is chemotherapy's general ineffectiveness in treating conventional chondrosarcoma. There is also no standard systemic therapy for advanced cases of conventional chondrosarcoma, unlike other solid tumors. Various factors contributing to chemoresistance include a slow proliferation rate, the expression of the multidrug-resistance 1 gene P-glycoprotein leading to resistance to doxorubicin in vitro, increased activity of anti-apoptotic and prosurvival pathways (as evidenced by high expression of BCL-2 family proteins), and large areas of extracellular matrix with poor vascularity, which hinder the access of antineoplastic agents. Additionally, the rarity of these cancers makes conducting randomized clinical trials to evaluate systemic therapy efficacy more difficult. Current chemotherapy recommendations include cisplatin and doxorubicin, based on treatment regimens for osteosarcoma and Ewing sarcoma. Other combinations, such as Gemcitabine, Ifosfamide, Dasatinib, and Pazopanib, have been used but have shown limited success, particularly in dedifferentiated and metastatic cases.

Leading companies in chondrosarcoma treatment, such as Inhibrx and Servier, are currently evaluating their lead candidates at various stages of clinical development.

Know more about the rising chondrosarcoma market, visit: https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Emerging Chondrosarcoma Drugs

INBRX-109: Inhibrx
TIBSOVO (ivosidenib): Servier

Scope of the Chondrosarcoma Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chondrosarcoma Companies: Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others
Key Chondrosarcoma Therapies: INBRX-109, TIBSOVO (ivosidenib), and others
Chondrosarcoma Therapeutic Assessment: Chondrosarcoma current marketed and Chondrosarcoma emerging therapies
Chondrosarcoma Market Dynamics: Chondrosarcoma market drivers and Chondrosarcoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Chondrosarcoma Unmet Needs, KOL's views, Analyst's views, Chondrosarcoma Market Access and Reimbursement

To get detailed insights on the scope of our chondrosarcoma market report, visit: https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Chondrosarcoma Patient Share (%) Overview at a Glance
5. Chondrosarcoma Market Overview at a Glance
6. Chondrosarcoma Disease Background and Overview
7. Chondrosarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Chondrosarcoma
9. Chondrosarcoma Current Treatment and Medical Practices
10. Unmet Needs
11. Chondrosarcoma Emerging Therapies
12. Chondrosarcoma Market Outlook
13. Country-Wise Chondrosarcoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Chondrosarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Chondrosarcoma Market Outlook 2034 https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Chondrosarcoma Pipeline Insights, DelveInsight

"Chondrosarcoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chondrosarcoma market. A detailed picture of the Chondrosarcoma pipeline landscape is provided, which includes the disease overview and Chondrosarcoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.